18 results about "Inhalation Solution" patented technology

The application discloses a modified bromhexine hydrochloride inhalation solution with enhanced stability and a preparation method thereof, and belongs to the technical field of medical preparations. The inhalation solution is mainly prepared from a targeting impurity control modified bromhexine hydrochloride inclusion compound, a special composite buffer mother liquor for inhibiting impurity B, inhalation grade sodium chloride, pharmaceutical grade sodium hydroxide and water for injection, and the pH value of the finished product is 4.5-5.5. The application constructs a three-stage progressive modification system, covalently grafts a mercapto-activated L-cysteine derivative onto hydroxypropyl-gamma-cyclodextrin to prepare a functional carrier, and realizes molecular-level isolation of bromhexine hydrochloride through host-guest inclusion, thereby blocking the generation of impurity B of bromhexine hydrochloride from the whole path, and solving the core pain points of easy impurity exceeding, short effective period and airway irritation of the existing product. The application can realize long-acting stable storage for 36 months, is suitable for the existing industrial production line, and has high clinical application and industrialization values.

The invention relates to a detection method of a revivacin inhalation solution, and belongs to the technical field of medicine detection. According to the detection method provided by the invention, a revivin inhalation solution sample is analyzed by adopting high performance liquid chromatography to obtain the content of impurities in the revivin inhalation solution; the high performance liquid chromatography uses a phosphate buffer as a mobile phase A and acetonitrile as a mobile phase B, and the elution conditions are as follows: 0-5 min, the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 95: 5 to 80: 20; the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 80: 20 to 20: 80 in 5-30 min; the volume ratio of the mobile phase A to the mobile phase B is 95: 5. The method provided by the invention can realize accurate detection of five different impurities in the revienacin inhalation solution, and is beneficial to actual production quality control and improvement of drug safety.

The application relates to the field of traditional Chinese medicine quality control, and particularly discloses a quality control method for Shuanghuanglian inhalation solution. The method can simultaneously determine the fingerprint spectrum and ingredient content of the Shuanghuanglian inhalation solution. The fingerprint spectrum detection method disclosed by the application adopts UPLC determination, has 17 characteristic peaks, and attributes 8 characteristic peaks. The contents of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, isochlorogenic acid B, isochlorogenic acid A, isochlorogenic acid C and forsythoside are simultaneously determined. Compared with the prior art, the method for determining the fingerprint spectrum and content of the Shuanghuanglian inhalation solution is improved, and the quality of the Shuanghuanglian inhalation solution can be comprehensively monitored conveniently, quickly and accurately.

The invention belongs to the technical field of biological medicines, and particularly relates to a honeysuckle total extract inhalation solution as well as a preparation method and application thereof. According to the invention, the honeysuckle total extract with poor water solubility, phospholipid and chitosan are innovatively and directionally assembled into the chitosan-phospholipid nanoparticles with uniform structure, and the nanoparticles are prepared by adopting a microfluidic technology. The strategy significantly improves the water solubility and stability of the honeysuckle total extract, and successfully prepares an inhalation solution suitable for pulmonary administration based on the nanoparticle dispersion system. The obtained preparation has the characteristics of high physical stability and good bioavailability potential. The honeysuckle total extract inhalation solution provided by the invention can effectively relieve the pathological process of the pyotoxic pneumonia through multiple mechanisms of remarkably inhibiting lung inflammatory response, relieving pulmonary edema, protecting the structural integrity of pulmonary alveoli and the like. Especially, a high-dose group shows a curative effect superior to that of a positive control drug, and a good dose-effect relationship is combined, so that the preparation has remarkable development potential and clinical transformation prospect in treatment of the septic pneumonia.

The application discloses a pirfenidone nanosuspension inhalation solution for treating interstitial pneumonia and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The pirfenidone nanosuspension inhalation solution is composed of the following components in 1000ml: 8-12g of pirfenidone hydrochloride, 4-6g of polyethylene glycol-poly-L-histidine block copolymer, 45-55g of mannitol, 0.4-0.6g of antioxidant, 0.05mol / L of citric acid-sodium citrate buffer, and water for injection, wherein the amount of the citric acid-sodium citrate buffer is appropriate, and the water for injection is added to 1000ml. The application adopts a pulmonary targeted inhalation administration path of non-gastrointestinal absorption, so that the drug directly acts on the lung interstitial lesion part by bypassing the intestinal absorption link.

The application discloses an inhaled solution medicine production line wastewater environment-friendly treatment device, which comprises a treatment tank, a storage tank for storing high-efficiency activated carbon powder, an agitating device for agitating liquid in the treatment tank and a stirring plate rotationally connected with the agitating device, and further comprises a material scattering device for scattering the high-efficiency activated carbon powder into the liquid for catalysis when the liquid enters the treatment tank. When the wastewater is added and enters a catalytic oxidation stage, hydrogen peroxide needs to be separately injected. If the linkage is not cut off, the liquid flow at the water inlet will trigger the blocking plate again, so that the excessive high-efficiency activated carbon enters the treatment tank. The sliding block drives the connecting rod to be displaced, so that the connecting rod is separated from the blocking plate, and mechanical limiting is realized through the key, so that the solid-liquid ratio in the tank is kept constant, and the influence of the excessive high-efficiency activated carbon on the subsequent catalysis is avoided.

The invention relates to the technical field of substance impurity detection methods, in particular to a procaterol hydrochloride inhalation solution related substance detection method which adopts high performance liquid chromatography for detection, and chromatographic conditions are as follows: mobile phases include a mobile phase A and a mobile phase B; the mobile phase A is a phosphate buffer solution, and the mobile phase B is methanol. The method can effectively detect the related substances in the procaterol hydrochloride inhalation solution, has the advantages of strong specificity, high sensitivity and comprehensive impurity control, and can better control the quality of a preparation.

The invention relates to a revienacin inhalation solution and a preparation method thereof. The revienacin inhalation solution comprises revienacin, a stabilizing agent, a buffering agent and water for injection, wherein the stabilizer is disodium edetate and propylene glycol, and the mass volume ratio of the disodium edetate to the propylene glycol is (0.05-0.1) g: (50-300) ml. The revivin inhalation solution can effectively delay degradation of revivin under the high-temperature condition, the long-term stability of a preparation under the high-temperature condition is guaranteed, the preparation prescription and the preparation process are simple and easy to operate, and the revivin inhalation solution is suitable for large-scale industrial production.

The invention provides an inhalation solution for bronchial constriction maintenance treatment of a chronic obstructive pulmonary disease patient and a preparation method of the inhalation solution, and relates to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: adding 50-95% of water for injection into a liquid preparation tank, cooling the water for injection to 50 DEG C, starting stirring, synchronously and sequentially adding sodium chloride, citric acid and sodium citrate according to the prescription dosage, stirring to dissolve the sodium chloride, the citric acid and the sodium citrate, continuously cooling to 40 DEG C, adding formoterol fumarate according to the prescription dosage, stirring to dissolve for 60 minutes, fixing the volume, and stirring again for 10 minutes for later use. According to the preparation method of the formoterol fumarate inhalation solution provided by the invention, process parameters are accurately controlled, so that the sterility guarantee level of the formoterol fumarate inhalation solution can be improved, the increase of the impurity content can be effectively controlled, and good stability of the formoterol fumarate inhalation solution is ensured.

This invention relates to a polymyxin inhalation liquid formulation and its preparation method, comprising 0.1-5% (w / v) polymyxin B sulfate, 0.05-1% (w / v) stabilizer, 0.1-0.9% (w / v) osmolarity regulator, pH adjuster, and solvent; the pH of the liquid formulation is 3.0-6.0; the solvent is selected from purified water and water for injection; the polymyxin inhalation solution provided by this invention has a simple composition, a pH of 3.0-6.0, and is osmotonic, which can reduce bronchospasm and cough caused by polymyxin inhalation solution. Safety evaluation has verified that it has good safety, providing a new option for clinical application.

The invention discloses a medicine assembly containing an etimicin sulfate solution and application of the medicine assembly. The medicine assembly comprises (a) the etimicin sulfate solution; the vibrating screen atomizer is used in cooperation with the etimicin sulfate solution; 1500-2200 micropores are formed in the central area of an atomizing sheet of the vibrating screen atomizer; the diameter of each micropore is 2.2 microns to 3.8 microns; wherein the vibration frequency of the vibrating screen atomizer is 90-120KHZ; the sections of the micropores in the vibrating screen atomizer are distributed in a step shape, and the taper is 18 degrees. The nebulizer is matched with the etimicin sulfate inhalation solution for use, so that the administration efficiency of the etimicin sulfate inhalation solution is improved, and the medicine can safely reach an effective treatment concentration in the lung. In addition, the form can improve the amount of delivered medicine, can deposit a large amount of medicine in terminal bronchus and pulmonary alveoli, increases the proportion of fine fog drops reaching the lung, shortens the atomization time, and reduces the volume of medicine liquid residues.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to an epimedin C solution for inhalation as well as a preparation method and application thereof. The preparation provided by the invention can improve the bioavailability of the epimedin C, enhance lung targeting, reduce systemic toxicity and improve the stability of the epimedin C, can effectively treat lung inflammation, and has a good application prospect.

The invention relates to the technical field of discharge leak detection, and particularly discloses a discharge leak detection device and method after procaterol hydrochloride inhalation solution packaging, and the method comprises the steps: carrying out the real-time collection of the surface image data of each electrode of a procaterol hydrochloride inhalation solution packaging bottle in the leak detection process through an image collection module; the roughness characteristics in the surface image data of each electrode are cleaned and corrected through the data cleaning module, so that the accuracy of the roughness characteristic data can be improved, reliable data support is provided for subsequent analysis of real-time pollution conditions of different electrodes, and the analysis accuracy of the real-time pollution conditions of different electrodes is improved. And then actual output current values of different electrodes are calculated based on pollution conditions of different electrodes, so that dynamic adjustment of a current monitoring threshold can be realized, and the accuracy of a comparison result of the current values near different electrodes and the current monitoring threshold in a leak detection process is improved. Further, the accuracy of the analysis result of the sealing performance of the procaterol hydrochloride inhalation solution packaging bottle is improved.

A fudosteine nebulization inhalation solution composition and use thereof. The fudosteine nebulization inhalation solution consists of fudosteine, a pH-adjusting agent and water. The droplet particle size of the composition is as follows: the D90 particle size is 7.0-10.0 μm, the D50 particle size is 2.8-4.5 μm, and the Dio particle size is 0.5-1.5 μm; and the percent deposition of the particles with the aerodynamic particle size of 1.4-5.4 μm in the fudosteine inhalation solution is not less than 50%. In addition, further provided is a drug assembly for use in conjunction with the nebulization inhalation solution, comprising the inhalation composition, and a nebulizer and a nebulizing cup with specific parameters. The fudosteine nebulization inhalation solution composition and the assembly thereof have the advantages of a small effective dose, acting fast, high drug delivery efficiency, and the like, and are particularly effective in treating tracheal and main bronchial diseases.

The invention relates to the field of pharmaceutical preparation detection, in particular to a method for determining the delivery rate and the total delivery amount of a formoterol fumarate inhalation solution. The invention provides a method for measuring the delivery rate and the total delivery amount of a formoterol fumarate inhalation solution, which comprises the following steps: firstly, using methanol as a diluent, then using water as the diluent, and emphasizing the sequence, so that active substances in a filter membrane can be better infiltrated, dissolved and collected; and the active substances of the medicine collected by the filter membrane are fully dissolved and leached, so that the determination result is more accurate and consistent with the theoretical result. Through verification, the system applicability, the accuracy, the precision, the linearity and the range of the determination method provided by the invention all meet the requirements, the accuracy is good, the precision is high, a new method is provided for determining the delivery rate and the total delivery amount of the formoterol fumarate inhalation solution, and the quality of the formoterol fumarate inhalation solution can be better controlled and evaluated.

This invention belongs to the field of new pharmaceutical technology and relates to a nebulized inhalation formulation for treating chronic obstructive pulmonary disease (COPD) and asthma, and its preparation method. Specifically, it relates to a nebulized inhalation solution formulation of an aminotetraphenylporphyrin photosensitizer (D4) with high light sensitivity. This invention uses an aminotetraphenylporphyrin photosensitizer (D4) as the active ingredient for treating COPD and asthma. The prepared D4 nebulized inhalation formulation comprises the following components: 200-400 μg / ml of the small molecule compound D4 solution, 0.1%-0.6% w / w acrylic polymer carbopol / 3%-25% w / w poloxamer 407 / 3%-25% w / w poloxamer 188, appropriate amounts of isotonic agent, pH adjuster, and purified water. The D4 nebulized inhalation formulation prepared by this invention, after excitation with a 650nm laser, shows significant therapeutic effects on COPD and asthma. After treatment, the alveolar septa narrowed, inflammatory infiltration decreased, airway changes were alleviated, and the thickness of the airway wall, smooth muscle layer, and basement membrane layer decreased. This method is highly effective, low in toxicity, highly targeted, has high nebulization efficiency, a short treatment cycle, and the preparation method is simple, convenient, and reliable, facilitating the establishment of quality control standards in production and promoting drug quality monitoring and large-scale production.

The invention relates to the technical field of biomedicine, in particular to a production process of a formoterol fumarate inhalation solution. Weighing raw materials and auxiliary materials; performing preparation; the method comprises the following steps: sampling a formoterol fumarate inhalation solution, and detecting the pH value; sterilizing and filtering; carrying out sterile filling and sealing, and sequentially carrying out forming inspection, filling volume inspection and visible foreign matter inspection; spraying codes; carrying out leak detection and light detection in sequence, and respectively detecting the sealing performance and visible foreign matters; packaging with aluminum bags; the formoterol fumarate inhalation solution prepared through the method has the advantages of being uniform in quality and high in production quality, the production quality of the formoterol fumarate inhalation solution is guaranteed, and the medicine taking effect of a patient is guaranteed.

This invention provides a method for determining impurities in ipratropium bromide inhalation solution, belonging to the field of pharmaceutical detection technology. The method involves preparing a test solution from the ipratropium bromide solution, using a mixture of ammonium acetate buffer and acetonitrile as mobile phase A and an acetonitrile mixture as mobile phase B, followed by isocratic elution at a volume ratio of 30:70 and high-performance liquid chromatography (HPLC) to detect impurities sulfur and butylated hydroxytoluene (BHT) in the ipratropium bromide solution. This invention employs HPLC, resulting in more accurate and consistent results with theoretical predictions. Furthermore, the method exhibits satisfactory recovery and specificity, high accuracy, and high precision. It provides a novel and accurate method for determining sulfur (S) and BHT in ipratropium bromide inhalation solution, enabling better quality control and evaluation of ipratropium bromide inhalation solutions.